IVC Filter Litigation (Bard & Cook Medical)

Inferior vena cava (IVC) filters are small, cage-like metal devices implanted in the inferior vena cava — the largest vein in the body, carrying blood from the lower body to the heart — to catch blood clots and prevent potentially fatal pulmonary embolism. Originally designed as permanent implants, 'retrievable' or 'optional' IVC filters were developed with the intention of being removed once the temporary risk of pulmonary embolism subsided.

The critical problem emerged when studies and FDA data revealed that retrievable IVC filters were frequently left in patients far longer than clinically intended — sometimes permanently — due to inadequate follow-up protocols and poor physician-patient communication. The longer a filter remains implanted, the greater the risk of serious complications including device fracture (with fractured struts migrating through the bloodstream to the heart or lungs), filter tilting or migration, perforation of the vena cava wall (with struts penetrating adjacent organs), and paradoxical embolism (clots forming on the filter itself).

The FDA issued safety communications in 2010 and 2014 recommending removal of retrievable IVC filters as soon as clinically feasible — typically within 29 to 54 days of implantation. Despite these warnings, retrieval rates remained low, with some studies showing fewer than one-third of retrievable filters were actually removed.

Studies have shown that the longer an IVC filter remains implanted, the greater the risk of complications. Research published in JAMA Internal Medicine and the Journal of Vascular and Interventional Radiology documented fracture rates up to 40% in certain filter models over extended implantation periods.

The FDA received over 900 adverse event reports related to IVC filters between 2005 and 2010 — including reports of device migration, filter fracture with embolization of fragments, and perforation of the vena cava — prompting the agency's 2010 safety communication.

C.R. Bard's Recovery and G2 filter models were particularly implicated, with internal Bard documents produced in litigation suggesting the company was aware of elevated fracture and complication rates but continued marketing the products. One internal Bard document reportedly projected that its Recovery filter would be associated with '12 deaths within 2 years' based on adverse event data.

Patients who received an IVC filter — particularly C.R. Bard (Recovery, G2, G2 Express, Eclipse, Meridian) or Cook Medical (Celect, Günther Tulip) models — and experienced complications such as filter fracture, migration, tilting, perforation of the vena cava or adjacent organs, or difficulty with filter retrieval may be affected.

This eligibility information is general and informational only. Consult a licensed attorney.

Significant settlements have already been reached, particularly by C.R. Bard/Becton Dickinson, which has settled thousands of IVC filter claims. The Bard IVC filter MDL (No. 2641) is in the District of Arizona.

Cook Medical IVC filter litigation continues in the Southern District of Indiana. Cook has not reached a global settlement, and cases continue to be litigated.

Remaining cases in both litigation tracks continue to be processed.

C.R. Bard argued that its IVC filters were FDA-cleared, appropriately designed, and that the complications were known risks of any IVC filter procedure. The company emphasized that IVC filters are life-saving devices that prevent fatal pulmonary embolism. Bard settled thousands of cases.

Cook Medical has maintained a more aggressive litigation posture, arguing that its filters have favorable safety profiles and that complications result from clinically appropriate decisions to leave filters in place rather than product defects.

C.R. Bard/Becton Dickinson has settled thousands of IVC filter claims. Individual settlement amounts are confidential but have reportedly varied based on the specific complication experienced, the need for surgical intervention, and the severity of injury.

Cook Medical IVC filter litigation continues without a global settlement.

Past settlement amounts are not a guarantee of future results.